Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 16/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 14/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.47 |
| ▸ | LTK | P29376 | 1/20 | 0.47 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028645 | 1.00 | S1PR5 (0.52) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL11942484 | 1.00 | S1PR5 (0.52) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL18532963 | 1.00 | S1PR5 (0.52) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL15942698 | 0.89 | S1PR5 (0.51) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL19646477 | 0.88 | S1PR5 (0.50) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL18532967 | 0.88 | S1PR5 (0.50) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL20610830 | 0.88 | S1PR5 (0.50) | S1PR5S1PR1HTR2AKCNH2SIGMAR1 | |
| SCHEMBL12471529 | 0.88 | ENPP2 (0.52) | S1PR5KCNH2SIGMAR1ENPP2 | |
| SCHEMBL11942471 | 0.87 | FAAH (0.43) | S1PR5S1PR1ENPP2 | |
| SCHEMBL11032487 | 0.87 | FAAH (0.43) | S1PR5S1PR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2017-08-24 | — | — | US | disclosed |
| US-9572824-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. | 2016-05-12 | — | — | US | disclosed |
| US-9186367-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BOIGEN MA INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2461683-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129023-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885S1PR1 1/4885HTR2A 246/4885 |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885S1PR1 1/4885HTR2A 246/4885 |
| US-20170239280-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 5/4885S1PR1 1/4885HTR2A 776/4885 |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885S1PR1 1/4885HTR2A 246/4885 |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 5/4885S1PR1 1/4885HTR2A 776/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | S1PR5 6/4885S1PR1 1/4885HTR2A 246/4885 |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | S1PR5 5/4885S1PR1 1/4885HTR2A 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.